 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On December 5, 2024, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (MMWR) entitled Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024. This report summarizes the new use of Heplisav-B in pregnant persons.
On September 11, 2024, the Food and Drug Administration (FDA) approved a request to update the labeling for Heplisav-B vaccine with new indications for use among pregnant persons. On that same date, FDA approved updates to the package insert for Heplisav-B [HepB vaccine (recombinant), adjuvanted], Section 8.1 (Pregnancy) to include human data that do not suggest an increased risk for both major birth defects and miscarriage.
Providers are recommended to administer Engerix-B, Heplisav-B, Recombivax HB, or Twinrix to pregnant persons needing HepB vaccination.
Thank you for all you do!
Oakland County Health and Human Services, Immunization Action Plan
|
